Clinical trials: Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
- Trial name
- NCT06345755
- Testing
- VX-407, Midazolam
- Where
- 2 sites in United States, Canada
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney Disease
Clinical Implications of DNA Analysis on ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disease. We plan DNA analysis using the next generation sequencer (NGS) and examine the relationship between mutational types and clinical phenotypes.
- Trial name
- DNAAA (NCT02322385)
- Where
- 2 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Kyorin University
Autosomal Dominant Polycystic Kidney Disease, Glomerular Filtration Rate > 40 ml/Min
Effects of Somatostatin on ADPKD Heart
Autosomal dominant polycystic kidney disease (ADPKD) is associated with early onset hypertension and left ventricular (LV) hypertrophy.
- Trial name
- NCT02119013
- Testing
- Octeotride
- Volunteers
- 35 people
- Sponsor
- Federico II University
Autosomal Dominant Polycystic Kidney
GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GBP-213 in patients with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT07891364
- Testing
- GBP-213
- Where
- China
- Volunteers
- 24 people
- Sponsor
- RenJi Hospital
Polycystic Kidney Disease
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
The goal of this pilot study is to evaluate the feasibility of administering niacinamide to patients with autosomal dominant polycystic kidney disease, to develop methods to assess the biological efficacy of niacinamide, and to…
- Trial name
- NIAC-PKD1 (NCT02140814)
- Testing
- Niacinamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alan Yu, MB, BChir
Somatostatin Analogs, Polycystic Liver Disease
Pasireotide LAR in Severe Polycystic Liver Disease
The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.
- Conditions
- Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease
- Trial name
- SOM230 (NCT01670110)
- Testing
- Pasireotide LAR
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
New Phenotype (Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia)
Research Into the Molecular Bases of a New Phenotype Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia
This study involves a single family, including 1 patient, father, mother and sister. The patient presented with a new phenotype associating premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia.
- Trial name
- BCL-2 (NCT03651388)
- Where
- France
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Kidney, Polycystic, Autosomal Dominant
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)
This phase II study examines the safety and efficacy of combination therapy for hypertension in patients with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT00890279
- Testing
- Cilnidipine, Imidapril
- Where
- 9 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease
The primary aim of this observational exploratory study is to develop AI-based image processing methods to advance the characterization of Polycystic Kidney Disease using medical images and associated clinical data, including: 1.
- Trial name
- AI4PKD (NCT06688981)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Polycystic Kidney Disease, Adult
Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
This is a Phase 3, open-label, roll-over study to demonstrate the continued hepatic and non-hepatic safety and renal efficacy of lixivaptan in participants with ADPKD who previously experienced abnormal liver chemistry test…
- Trial name
- NCT05208866
- Testing
- Lixivaptan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Palladio Biosciences
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Liver Cyst, Polycystic Liver Disease
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
Patients with large hepatic cysts (> 5cm) may develop symptoms. These can be captured with the polycystic liver disease questionnaire (PLD-Q).
- Conditions
- Liver Cyst, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney, Autosomal Dominant Polycystic Liver Disease
- Trial name
- ATLAS (NCT05500157)
- Testing
- aspiration sclerotherapy versus laparoscopic fenestration
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
Autosomal Dominant Polycystic Kidney Disease
Tolvaptan-Octreotide LAR Combination in ADPKD
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a leading cause of End Stage Kidney Disease (ESKD) worldwide. Elevated levels of 3', 5' - cyclic AMP (cAMP) play a central role in the pathogenesis and progression of the…
- Trial name
- TOOL (NCT03541447)
- Testing
- Tolvaptan, Octreotide LAR
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Adult Polycystic Kidney Disease, Kidney Neoplasms
Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function
The number of people with kidney disease is constantly rising and renal failure represents one of the major health care burdens globally.
- Conditions
- Adult Polycystic Kidney Disease, Kidney Neoplasms, Kidney Dysfunction
- Trial name
- NCT03442647
- Testing
- sinistrin clearance dynamic measurement
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Thomas Mueller
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide was shown in experimental studies to inhibit the cyst formation and growth in ADPKD models, while triptolide-containing formulation was revealed to potentially slow the disease progression in several proteinuric ADPKD…
- Trial name
- NCT02115659
- Testing
- Triptolide-Containing Formulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Changzheng Hospital
Polycystic Kidney Disease
Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
Funding Source - FDA OOPD Pioglitazone is currently used in clinical practice to treat diabetes and this study will examine the potential use of a low dose of the same drug for the treatment of polycystic kidney disease.
- Trial name
- PIOPKD (NCT02697617)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Autosomal Dominant Polycystic Kidney Disease
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of this study is to compare the short-term effects of two tolvaptan formulations in patients with ADPKD.
- Trial name
- NOCTURNE (NCT01451827)
- Testing
- Tolvaptan MR, Tolvaptan IR
- Where
- 35 sites in United States
- Volunteers
- 178 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADPKD
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A mild reduction in food intake significantly inhibits renal cyst growth in mouse models of ADPKD. The underlying mechanism was unknown at the time.
- Trial name
- Keto-ADPKD (NCT04680780)
- Testing
- Ketogenic diet, 3-days water-fasting, Control
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- University of Cologne
Polycystic Kidney, Autosomal Dominant
Feasibility Study of Metformin Therapy in ADPKD
This study is being done to determine if treatment with metformin, a drug widely used for the treatment of diabetes type 2, is safe and well tolerated by individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who…
- Trial name
- NCT02903511
- Testing
- Metformin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Colorado, Denver
Polycystic Kidney, Autosomal Dominant
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
This study will test to see if metformin is safe and if it is tolerated compared to placebo in adult Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients with beginning stages of chronic kidney disease.
- Trial name
- TAME (NCT02656017)
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- Kyongtae Ty Bae, M.D., Ph.D.